Follow us on




Q of the week

Q: How Do You Get Shingles?

Get the Answer: 

Prototype devices

It is recognized that a manufacturer may wish to submit a small number  of "prototype models" of a device to clinical investigation in order to assess safety and/or performance; and those such prototypes may need to undergo a number of changes prior to large-scale production.

 Forums
Welcome Guest   [Register]  [Login]
EFGCP–EUCROF Joint Workshop Final Report   by  on 2010-08-20 20:12:20
Managing Clinical Trials   by  on 2010-07-16 00:05:32
US-FDA issues Revised Info Sheet Guidance on Clinical Investigator Disqualification   by  on 2010-06-13 18:11:41
US-FDA issues final guidance on Statement of Investigator (Form FDA 1572)   by  on 2010-06-13 18:07:59
Rising Clinical Trial Complexity Continues to Vex Drug Developers   by  on 2010-06-03 17:36:33
Investigator-Driven Clinical Trials: An ESF Forward Look   by  on 2010-06-03 17:27:58
NIH's Financial Conflict of Interest (FCOI) Proposed Rule   by  on 2010-05-27 19:42:00
AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population   by  on 2010-05-13 19:39:54
Argentina: ANMAT - new regulatory update   by  on 2010-05-01 09:40:32
The Wall Street Journal's special supplement on clinical trials   by  on 2010-05-01 09:31:52
Major developments in EU Clinical Trial Guidances   by  on 2010-04-21 03:10:55
Analysis of the adverse reactions induced by natural product-derived drugs   by  on 2010-04-19 07:16:06
Newer Antibacterial Drugs for a New Century   by  on 2010-04-19 06:49:47
Newer Non-Statin Drugs for Reducing Cholesterol   by  on 2010-04-13 15:57:20
Practice Guidelines for Chronic Pain Management   by  on 2010-04-05 04:52:16
CONSORT III (2010)   by  on 2010-03-29 20:53:28
US FDA Draft Guidance on Pharmacokinetics in Patients with Impaired Renal Function   by  on 2010-03-20 20:25:16
US-FDA issues First Draft Guidance on Noninferiority Trials   by  on 2010-03-04 22:07:46
US FDA new rule on reporting information regarding falsification of data   by  on 2010-02-26 04:47:33
US-FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials   by  on 2010-02-06 20:12:14
 Subject :Chinese patent policy proposals raise concerns for innovators.. 2010-01-12 00:31:21 
Harrison
Newbie
Joined: 2009-07-13 23:53:04
Posts: 31
Location
  • 4294967292

Proposed new regulations in China on the formulation and revision of national intellectual property (IP) standards involving patents contain several worrying provisions for IP holders, at least in the view of one expert observer.

The Standards Administration of China (SAC) issued the proposed regulations in November and has since been gathering public comments from a wide range of stakeholders. But, as currently worded, the draft regulations are "out of synch with the patent policies of international standards setting organisations and will negatively impact…innovation within China", George Willingmyre writes on Intellectual Property Watch's blog.

The author, president of standards and trade policy consultancy GTW Associates, highlights several proposals he sees of concern. For example, article nine of the SAC draft states that if an existing patent must be licensed to help implement a national standard, this will be done "at a price significantly lower than the normal royalties".

This is a condition not set by other major standards-setting bodies, and may discourage IP owners inside and outside China and impede the adoption of appropriate standards by China, Mr Willingmyre says in the blog (entries to which Intellectual Property Watch notes are solely those of the authors and are not associated with it).

He also points to article 13 of the SAC proposal, which outlines procedures for the compulsory licensing of patents. This says that, in principle, compulsory national standards shall not involve patents. But for those that do, patentees shall grant these free of charge. If agreement cannot be reached, the release of standards will be temporarily withheld or a compulsory licence granted according to law, it states.

"Compulsory licensing should be used rarely and in limited extraordinary circumstances" and within the global rules of the World Trade Organization's TRIPS agreement, Mr Willingmyre warns. The SAC would do well to consider co-ordinating its regulations in this area with other policy bodies in China, and laying out clearer guidelines which limit such licensing to critical extraordinary circumstances using well-defined criteria, he suggests.

China's State Council released a national IP strategy blueprint in 2008, which highlighted the need to significantly improve IP protection and enforcement to help drive the country's economic growth. It has since been moving to strengthen its patent laws, although major trading partners remain concern over whether these will be effectively enforced in practice.

Source: Scrip News

IP Logged
Page # 


Powered by ccBoard